Antineoplastics
1
Reactions 562 - 5 Aug 1995 Antineoplastics Supravenous hyperpigmentation: case report Although pigmentary changes are a well known adverse effect of antineoplastic agents, the following case involves an unusual pattern of linear supravenous hyperpigmentation of the forearms with no evidence of skin inflammation or thrombophlebitis. A 44-year-old woman developed a streaky brown skin pigmentation on the skin above the veins in both of her forearms after she received her third cycle of IV antineoplastic therapy in the veins of both hands and forearms. Each cycle included cyclophosphamide 750 mg/m 2 , doxorubicin 50 mg/m 2 and vincristine 2mg on day 1 and prednisone 100mg on days 1–5. She also received filgrastim 5 µg/kg/day between cycles. During the following 3 cycles of antineoplastic therapy, the woman’s hyperpigmentation increased, and then slowly faded within 2 months after antineoplastic therapy was stopped. Author comment: ‘It remains unclear which agents caused the supravenous hyperpigmentation. Both cyclophosphamide and doxorubicin may induce hyperpigmentation.’ Schulte-Huermann P, et al. Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma. Dermatology 191: 65-67, 1995 - Germany 800374386 1 Reactions 5 Aug 1995 No. 562 0114-9954/10/0562-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 562 - 5 Aug 1995
Antineoplastics
Supravenous hyperpigmentation: case reportAlthough pigmentary changes are a well known adverse
effect of antineoplastic agents, the following case involves anunusual pattern of linear supravenous hyperpigmentation ofthe forearms with no evidence of skin inflammation orthrombophlebitis.
A 44-year-old woman developed a streaky brown skinpigmentation on the skin above the veins in both of herforearms after she received her third cycle of IV antineoplastictherapy in the veins of both hands and forearms. Each cycleincluded cyclophosphamide 750 mg/m2, doxorubicin 50mg/m2 and vincristine 2mg on day 1 and prednisone 100mg ondays 1–5. She also received filgrastim 5 µg/kg/day betweencycles.
During the following 3 cycles of antineoplastic therapy, thewoman’s hyperpigmentation increased, and then slowly fadedwithin 2 months after antineoplastic therapy was stopped.
Author comment: ‘It remains unclear which agents causedthe supravenous hyperpigmentation. Both cyclophosphamideand doxorubicin may induce hyperpigmentation.’Schulte-Huermann P, et al. Supravenous hyperpigmentation in association withCHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.Dermatology 191: 65-67, 1995 - Germany 800374386
1
Reactions 5 Aug 1995 No. 5620114-9954/10/0562-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
